Clinical Trial
A Phase 2 Study to Investigate Ubamatamab With and Without REGN7075 in Treatment-Experienced Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
Learn more about this study at
clinicaltrials.gov
For more information contact us here:
Phone
800-600-3606Brief Summary
This study will evaluate two study drugs called ubamatamab and REGN7075, to see if they can help treat advanced or metastatic Non-Small Cell Lung Cancer (NSCLC), and sarilumab, to evaluate to see if it can help with immune-related side effects from ubamatamab.
The study is looking at:
* How well ubamatamab and REGN7075 works
* The side effects that ubamatamab and REGN7075 might cause
* How much ubamatamab and REGN7075 is in the blood at different times
* If the body makes antibodies to ubamatamab and/or REGN7075, this may cause the ubamatamab to not work as well
Protocol Interventions
Drug: Ubamatamab, Drug: REGN7075, Drug: Sarilumab
Learn About Clinical Trials
Clinical trials are research studies that help us find new ways to prevent, diagnose, and treat cancer. If you are interested in participating in a clinical trial, our team will help you find a study that is right for you. Call us to speak with a Siteman care coordinator.